A curated, public list of human 'protective' genetic variants (with effects and harms) lowers the barrier for consumer embryo selection, DIY gene edits, and commercial enhancement markets by turning scattered literature into an actionable reference. Making such inventories public changes who can act on genetic enhancement (clinics, startups, parents, biohackers) and what regulation or safeguards are needed.
— The existence and circulation of a concrete catalog reframes genomic enhancement from speculative ethics to an operational, regulable market and biosafety problem.
Jake Currie
2026.11.12
78% relevant
The paper identifies loss of CASS4 as worsening plaque pathology and cognitive signs in mice, making CASS4 a candidate for inclusion in databases or 'protective‑allele' registries that inform risk stratification, clinical screening, and potential gene‑targeted interventions; the actor is the University of Virginia team (Addie Walsh, John Lukens) and their Journal of Experimental Medicine study.
2026.04.04
100% relevant
Harvard Church lab page listing specific variants (e.g., CCR5 -/-, PCSK9 -/-, APOE E2/E2) with both benefits and potential negatives.
← Back to all ideas